List of Jelmyto drug patents

Jelmyto is owned by Urogen Pharma.

Jelmyto contains Mitomycin.

Jelmyto has a total of 2 drug patents out of which 0 drug patents have expired.

Jelmyto was authorised for market use on 15 April, 2020.

Jelmyto is available in powder;pyelocalyceal dosage forms.

The generics of Jelmyto are possible to be released after 20 January, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9950069 UROGEN PHARMA Material and method for treating internal cavities
Jan, 2031

(7 years from now)

US9040074 UROGEN PHARMA Material and method for treating internal cavities
Jan, 2031

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 15, 2027
New Product (NP) Apr 15, 2023

Drugs and Companies using MITOMYCIN ingredient

Market Authorisation Date: 15 April, 2020

Treatment: NA

Dosage: POWDER;PYELOCALYCEAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in